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cant. HighBAI/highBDI was signiﬁcantly different than the other
groups (p < 0.01). This pattern was similar for social function,
role emotion, mental health. Physical-related SF-36 domains
were generally not different between groups. The difference in
work-performance scale scores followed the same general pattern
of less impairment with lowBAI/lowBDI (for example, WPAI-
Percent Impairment While Working scale 0.22 + 0.3) and
highBAI/highBDI (WPAI Percent Impairment While Working
0.77 + 0.2), p < 0.01. Other work scales followed a similar
pattern. BDI routinely was more signiﬁcant in regression models
compared to BAI. CONCLUSION: Comorbid anxiety and
depression greatly impair patients. Clinicians and researchers
should measure the presence and severity of both mental illnesses
when assessing their inﬂuence on health-related quality of life
and work-performance.
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OBJECTIVE: While the clinical efﬁcacy of drugs for ADHD is
widely studied in clinical trials (usually randomised controlled
trials, RCTs), patient preferences with regard to their treatments
are not well understood and therefore considered to a less extent.
Aim of this study therefore was to explore the patients’ percep-
tions of an “ideal treatment” for ADHD. METHODS: Exami-
nation of the state of the art as reported in the literature was
followed by a qualitative study with four focus groups consisting
of 6–8 parents of ADHD-patients each. In a subsequent quanti-
tative study phase, data was collected in an online or paper-pencil
self-ﬁll-in questionnaire for parents of patients and patient (age
>14 years) themselves. It included sociodemographic data, treat-
ment history and actual treatment and patients’ preferences of
therapy characteristics using direct measurement (23 items on
a 5-point Likert-scale) as well as a discrete-choice-experiment
(DCE, 8 pairs with 6 characteristics). RESULTS: N = 213 ques-
tionnaires were ﬁlled; most of them by the parents of patients
(79% by the mothers, 9% by the fathers). Most of the patients
were male (83%) and most of them (83%) had actual medical
treatment of ADHD. Direct measurement showed “good emo-
tional quality of live”, “no addiction on medication”, “improve-
ment of concentration capability,” and “few side effects” in the
ﬁrst places. In the DCE, alternatives with “better social quality of
life (friendships etc. possible)”, “better emotional quality of life
(disease not all of the time mentally present)”, and “longer
duration of medication effect” were more likely to be chosen,
giving thus similar results. CONCLUSION: This unique study
demonstrates that it is possible to obtain valid and robust infor-
mation from patients on what constitutes relevant patient out-
comes. Such information should play a critical role in appraisal
of treatment alternatives by HTA bodies.
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OBJECTIVE: The functional rating scale (FRS) and clinical
dementia rating (CDR) scale are two different tests used to assess
the severity and progression of dementia. Although the FRS
covers more domains and requires less time to administer than
the CDR, the CDR categorizes severity of dementia while the
FRS does not. The purpose of this research was to calculate the
agreement between the FRS and CDR scales and to determine if
they could be used interchangeably for diagnosis of disease sever-
ity in vascular dementia (VaD). METHODS: Inpatients and out-
patients diagnosed with VaD/mixed VaD were evaluated using
the FRS and CDR scales. The tests were administered indepen-
dently by two separate raters. Since the FRS contains all of the
domains that are rated in the CDR, CDR scores were extracted
from the corresponding FRS domains and used to derive global
scores of severity. FRS-derived global scores were then compared
to original CDR global scores by a weighted kappa analysis to
measure concordance. RESULTS: A total of 28 VaD/mixed VaD
patients were involved in the study. In the patient population,
60.7% were males and average age was 78.6  7.7 years.
Average MMSE score was 19.9  4.8 while mean Hachinski
score was 8.1  2.8. The modal value obtained for both the
FRS-derived CDR scores and original CDR scores was 2; in both
groups scores ranged from 0.5–3 with 43% of patients diagnosed
in category 2 (moderate dementia). The weighted kappa analysis
showed substantial concordance (kappa = 0.75) between FRS-
derived CDR and original CDR-global scores. CONCLUSION:
These results suggest that FRS scores can be used to derive global
scores that are in agreement with those produced by the validated
CDR method. This serves as a powerful tool since it allows for
easy comparison of the diagnostic distribution, natural history
and treatment outcomes of individuals with dementia.
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OBJECTIVE: Signal detection and, ultimately, regulatory
approval depend on high-quality, valid and reliable data. The
subjective rating scales utilized in CNS clinical trials may be
vulnerable to spurious ratings and intentional or unintentional
manipulation of ratings by investigators at screening or baseline
visits. The objective of this study was to evaluate the feasibility of
utilizing a patient reported outcome as a quality assurance
measure for evaluation of the quality of a clinician rated primary
efﬁcacy measure in a CNS clinical trial. METHODS: A propri-
etary ratings surveillance system was utilized in a multi-center,
double blind, randomized, placebo-controlled clinical trial in
which the Hamilton Anxiety Rating Scale (HARS) was the
primary efﬁcacy measure. The patient rated Beck Anxiety Inven-
tory (BAI) was added to the baseline visit for quality assurance
purposes. Based on published guidelines of the expected relation-
ship between HARS and BAI scores, a computer program ﬂagged
aberrant ratings and three ﬂags with the same rater triggered
a teaching intervention. The ratings surveillance system was
intended both to detect aberrant rating patterns and to deter
intentional inﬂation of ratings in order to qualify subjects.
RESULTS:The clinical trial is ongoing. 91 pairs of HARS and BAI
ratings have been examined from the randomization visit. 61/91
(67%) pairswere ﬂagged for discordance, inmost cases (79%) due
to disproportionately high HARS scores compared to the BAI. In
8 cases, the BAI was under 10 with the HARS 22 or greater. In 11
cases, there were at least 3 ﬂags for the same rater and the pattern
of discordance was considered to be of sufﬁcient clinical signiﬁ-
cance to warrant a teaching intervention. CONCLUSION: Use of
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